>欧洲子宫癌药物市场，按癌症类型（子宫内膜癌和子宫肉瘤）、治疗类型（化疗、激素治疗、靶向治疗、免疫治疗等）、药物类型（仿制药和品牌药）、年龄组（成人和老年人）、给药途径（口服和肠外给药）、最终用户（医院、癌症中心、专科诊所等）、分销渠道（直接招标、零售销售等）划分 - 行业趋势和预测到 2030 年。
欧洲子宫癌药物市场分析与洞察
欧洲子宫癌药物市场是肿瘤制药行业的一个重要领域，反映了全球子宫癌病例的日益普遍。子宫癌是最常见的妇科恶性肿瘤之一，多年来发病率一直在稳步上升。造成这一趋势的因素有很多，包括人口老龄化、肥胖症流行以及诊断能力的提高，从而可以更早发现。因此，随着制药公司开发创新疗法来满足面临这种具有挑战性的疾病的患者的需求，子宫癌药物市场不断扩大。
欧洲子宫癌药物市场的主要驱动因素包括研发的进步、对精准医疗的日益重视以及对子宫癌分子机制的不断了解。然而，市场面临着治疗成本高、缺乏熟练人员和监管要求复杂等挑战。
欧洲子宫癌药物市场预计将从 2022 年的 684,672.98 万美元增至 2030 年的 1,251,870.80 万美元，在 2023 年至 2030 年的预测期内以 8.4% 的复合年增长率增长。
|
报告指标 |
细节 |
|
预测期 |
2023 至 2030 年 |
|
基准年 |
2022 |
|
历史岁月 |
2021 (可定制为 2015-2020) |
|
定量单位 |
收入（千美元） |
|
涵盖的领域 |
癌症类型（子宫内膜癌和子宫肉瘤）、治疗类型（化疗、激素治疗、靶向治疗、免疫治疗等）、药物类型（仿制药和品牌药）、年龄组（成人和老年人）、给药途径（口服和肠外给药）、最终用户（医院、癌症中心、专科诊所等）、分销渠道（直接招标、零售销售等） |
|
覆盖国家 |
德国、法国、英国、意大利、西班牙、俄罗斯、土耳其、比利时、荷兰、瑞士和欧洲其他地区 |
|
涵盖的市场参与者 |
百特、礼来公司、Hikma Pharmaceuticals PLC、太阳制药工业有限公司、Fresenius SE & Co. KGaA、Viatris Inc.、赛诺菲、Teva Pharmaceuticals USA, Inc.、Amneal Pharmaceuticals LLC、默克公司、葛兰素史克公司、卫材株式会社、辉瑞公司和 Getwell Oncology 等 |
市场定义
子宫癌药物包括一类专门用于治疗和管理子宫癌的药物和疗法，子宫癌是一种源自子宫内膜（子宫内膜）的恶性肿瘤。这些药物在子宫癌患者的综合治疗和护理中起着至关重要的作用。它们的主要目的是靶向、抑制或消除子宫内的癌细胞，从而减缓或阻止疾病的进展并减轻相关症状，如异常子宫出血、盆腔疼痛和不适。
欧洲子宫癌药物市场动态
本节旨在了解市场驱动因素、限制因素、机遇和挑战。下文将详细讨论所有这些内容：
驱动程序
- 全球子宫癌发病率上升
近年来，全球子宫癌发病率显著上升，已成为欧洲的重大健康问题。全球子宫癌发病率上升是一个复杂而多方面的问题，受到遗传、生活方式、环境和医疗保健等多种因素的影响，推动了市场的增长。
- 子宫癌靶向治疗不断取得进展
子宫癌靶向治疗的进展有望改善治疗效果、减少副作用并提高患者的生活质量。靶向治疗是一种癌症治疗方法，它专注于癌细胞生长和扩散的特定分子或途径，而不是像传统化疗那样广泛影响快速分裂的细胞。
靶向疗法是专门针对癌细胞特定变化而设计的药物。它们对高风险或晚期子宫癌有帮助。
因此，子宫癌靶向治疗的不断进步正在推动市场的增长。
机会
- 基因组分析和生物标志物发现的进展
基因组分析和生物标志物发现方面的进步对子宫癌治疗产生了重大影响，为管理该疾病提供了更有针对性和个性化的方法。子宫癌包含多种亚型，这些进步有助于识别每种亚型特有的遗传变异和分子特征，从而制定更有效的治疗策略。这些进步改变了子宫癌治疗的格局，使人们更好地了解子宫癌亚型的遗传和分子特征，提供更有针对性的治疗方案，并提高早期检测的潜力。随着该领域研究的不断发展，它有望进一步改善患者的治疗效果，并扩大子宫癌患者可用的治疗方案范围。因此，基因组分析和生物标志物发现方面的进步有望成为市场增长的机会。
挑战/限制
- 子宫癌治疗费用高昂
子宫癌治疗的高昂费用是医疗保健领域的一个重大问题，对个人和医疗保健系统都有影响。
子宫癌通常需要多模式治疗，包括手术、放射治疗、化疗、靶向治疗和激素治疗。这些不同治疗方式的综合费用，加上相关的住院、咨询和随访，可能会显著增加治疗的总费用。子宫癌患者可能需要住院进行手术、化疗或放射治疗，从而导致住院、手术室费用和住院护理相关的大量费用。
因此，子宫癌治疗的高成本抑制了市场的增长。
- 子宫癌药物市场的监管障碍
子宫癌药物市场的监管障碍是影响新疗法开发、批准和可及性的关键因素。美国食品药品管理局 (FDA)、欧洲药品管理局 (EMA) 等监管机构负责确保药物的安全性、有效性和质量。这些机构制定了严格的标准和指导方针，公司在药物开发过程中必须遵守这些标准和指导方针。
子宫癌药物市场的监管障碍是多方面的，而且往往是长期的。因此，预计这将对市场增长构成挑战。
最新动态
- 2023 年 10 月，默克公司公布了第三阶段 KEYNOTE-A39 试验（也称为 EV-302）的结果，该试验与 Seagen 和 Astellas 合作，比较了默克公司的抗 PD-1 疗法 KEYTRUDA 和抗体药物偶联物 Padcev（enfortumab vedotin-ejfv）与化疗（吉西他滨加顺铂或卡铂）在先前未接受过治疗的局部晚期或转移性尿路上皮癌患者中的疗效。这有助于该公司扩大其品牌 KEYTRUDA 的应用范围
- 2023 年 10 月，礼来公司宣布收购 POINT Biopharma Global, Inc.，该公司的临床前和临床产品线中拥有用于精准治疗多种癌症的放射性药物。此次收购帮助该公司将肿瘤学能力扩展到下一代放射性配体疗法
- 2023 年 3 月，卫材株式会社宣布将在 2023 年 3 月 25 日于佛罗里达州坦帕举行的妇科肿瘤学会 (SGO) 女性癌症 2023 年年会和诊所发表两篇摘要。第九次科学全体会议：最佳研究会议将展示的值得关注的研究包括在欧洲再次接受铂类化疗的复发性或晚期子宫内膜癌患者的真实世界结果和医疗资源利用情况。此外，还展示了 LEAP（仑伐替尼和派姆单抗）临床项目的数据，该项目分析了关键性 3 期研究 309/KEYNOTE-775 中仑伐替尼 (LENVIMA) 和派姆单抗 (KEYTRUDA) 组合对晚期子宫内膜癌患者在任何环境下接受过至少一种铂类方案治疗后肿瘤的反应。该公司的这一举措是为了提高人们对 LENVIMA 治疗子宫内膜癌的认识
- 2023 年 3 月，Teva Pharmaceutical USA, Inc. 的子公司和 NATCO Pharma Limited USA 子公司 Teva Pharmaceuticals 宣布推出 Revlimid（来那度胺胶囊）的仿制药，额外提供 2.5 毫克和 20 毫克两种规格。两家公司于 2022 年 3 月在美国市场推出了四种额外规格的产品。在上市时，两家公司在美国市场销售所有规格的来那度胺
- 2022 年 12 月，赛诺菲和 Innate Pharma SA 宣布扩大合作，赛诺菲授权 Innate 的 ANKETTM（基于抗体的 NK 细胞接合剂治疗）平台开发针对 B7H3 的自然杀伤 (NK) 细胞接合剂项目。赛诺菲还可以选择添加最多两个额外的 ANKETTM 靶点。在选定候选药物后，赛诺菲将负责所有开发、制造和商业化工作。此次合作有助于扩大赛诺菲在市场上的肿瘤学产品组合
欧洲子宫癌药物市场范围
欧洲子宫癌药物市场根据癌症类型、治疗类型、药物类型、年龄组、给药途径、最终用户和分销渠道分为七个显著的细分市场。细分市场之间的增长有助于您分析利基增长领域和进入市场的策略，并确定您的核心应用领域和目标市场的差异。
癌症类型
- 子宫内膜癌
- 子宫肉瘤
根据癌症类型，市场分为子宫内膜癌和子宫肉瘤。
治疗类型
- 化疗
- 免疫疗法
- 激素治疗
- 靶向治疗
- 其他的
根据治疗类型，市场分为化疗、免疫疗法、激素疗法、靶向疗法和其他疗法。
药物类型
- 泛型
- 品牌
根据药品类型，市场分为仿制药和品牌药。
年龄组
- 老年
- 成年人
根据年龄组，市场分为老年人和成年人。
给药途径
- 肠外
- 口服
根据给药途径，市场分为非肠道给药和口服给药。
最终用户
- 医院
- 癌症中心
- 专科诊所
- 其他的
根据最终用户，市场分为医院、癌症中心、专科诊所和其他。
分销渠道
- 直接招标
- 零售销售
- 其他的
根据分销渠道，市场分为直接招标、零售销售和其他。
欧洲子宫癌药物市场区域分析/见解
欧洲子宫癌药物市场根据癌症类型、治疗类型、药物类型、年龄组、给药途径、最终用户和分销渠道分为七个显著部分。
本市场报告涵盖的国家包括德国、法国、英国、意大利、西班牙、俄罗斯、土耳其、比利时、荷兰、瑞士和欧洲其他地区。
由于该地区市场参与者的强大影响力，德国有望主导欧洲子宫癌药物市场。
报告的国家部分还提供了影响市场当前和未来趋势的各个市场影响因素和国内市场监管变化。新销售、替代销售、国家人口统计、监管法案和进出口关税等数据点是用于预测各个国家市场情景的一些主要指标。此外，在对国家数据进行预测分析时，还考虑了区域品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战，以及销售渠道的影响。
竞争格局和欧洲子宫癌药物市场份额分析
欧洲子宫癌药物市场竞争格局提供了竞争对手的详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、生产基地和设施、公司优势和劣势、产品发布、产品批准、产品宽度和广度、应用主导地位以及产品类型生命线曲线。以上提供的数据点仅与公司对市场的关注有关。
欧洲子宫癌药物市场的一些主要市场参与者包括百特、礼来公司、Hikma Pharmaceuticals PLC、太阳制药工业有限公司、Fresenius SE & Co. KGaA、Viatris Inc.、赛诺菲、Teva Pharmaceuticals USA, Inc.、Amneal Pharmaceuticals LLC、默克公司、葛兰素史克公司、卫材株式会社、辉瑞公司和 Getwell Oncology 等。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE EUROPE UTERINE CANCER DRUGS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 CANCER TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
5 EUROPE UTERINE CANCER DRUGS MARKET, REGULATORY FRAMEWORK
5.1 OVERVIEW
5.2 REGULATIONS IN EUROPE
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISING INCIDENCE OF UTERINE CANCER WORLDWIDE
6.1.2 GROWING ADVANCEMENTS IN TARGETED THERAPY FOR UTERINE CANCER
6.1.3 RISING AWARENESS OF UTERINE CANCER
6.1.4 RISING COLLABORATIONS AND PARTNERSHIPS AMONG LEADING PLAYERS
6.2 RESTRAINTS
6.2.1 HIGH COST OF UTERINE CANCER TREATMENT
6.2.2 SIDE EFFECTS AND TOXICITY ASSOCIATED WITH CANCER DRUGS
6.3 OPPORTUNITIES
6.3.1 ADVANCEMENTS IN GENOMIC PROFILING AND BIOMARKER DISCOVERY
6.3.2 GROWING R&D ACTIVITIES FOR UTERINE CANCER TREATMENT
6.4 CHALLENGES
6.4.1 REGULATORY HURDLES IN THE UTERINE CANCER DRUGS MARKET
6.4.2 DRUG RESISTANCE IN THE TREATMENT OF UTERINE CANCER
7 EUROPE UTERINE CANCER DRUGS MARKET, BY CANCER TYPE
7.1 OVERVIEW
7.2 ENDOMETRIAL CANCER
7.2.1 UTERINE CARCINOSARCOMA
7.2.2 SEROUS ADENOSARCOMA
7.2.3 ADENOSQUAMOUS CARCINOMA
7.2.4 OTHER
7.3 UTERINE SARCOMA
7.3.1 UTERINE LEIOMYOSARCOMA
7.3.2 ENDOMETRIAL STROMAL SARCOMAS
7.3.3 UNDIFFERENTIATED SARCOMA
8 EUROPE UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE
8.1 OVERVIEW
8.2 CHEMOTHERAPY
8.2.1 PACLITAXEL
8.2.2 CARBOPLATIN
8.2.3 CISPLATIN
8.2.4 DOXORUBICIN
8.2.5 DOCETAXEL
8.2.6 OTHERS
8.3 IMMUNOTHERAPY
8.4 HORMONE THERAPY
8.4.1 PROGESTINS
8.4.1.1 MEDROXYPROGESTERONE ACETATE
8.4.1.2 OTHERS
8.4.2 AROMATASE INHIBITORS
8.4.2.1 LETRAZOLE
8.4.2.2 ANASTRAZOLE
8.4.2.3 EXEMESTANE
8.4.3 LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS
8.4.3.1 GOSERELIN
8.4.3.2 LEUPROLIDE
8.4.4 OTHERS
8.5 TARGETED THERAPY
8.5.1 LENVATINAB
8.5.2 BEVACIZUMAB
8.5.3 MTOR INHIBITORS
8.5.3.1 EVEROLIMUS
8.5.3.2 TEMSIROLIMUS
8.6 OTHERS
9 EUROPE UTERINE CANCER DRUGS MARKET, BY DRUG TYPE
9.1 OVERVIEW
9.2 GENERICS
9.3 BRANDED
9.3.1 KEYTRUDA
9.3.2 LENVIMA
9.3.3 PROVERA
9.3.4 TEMODAR
9.3.5 JEMPERLI
9.3.6 OTHERS
10 EUROPE UTERINE CANCER DRUGS MARKET, BY AGE GROUP
10.1 OVERVIEW
10.2 GERIATRIC
10.3 ADULTS
11 EUROPE UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION
11.1 OVERVIEW
11.2 PARENTERAL
11.3 ORAL
12 EUROPE UTERINE CANCER DRUGS MARKET, BY END USER
12.1 OVERVIEW
12.2 HOSPITALS
12.2.1 PRIVATE
12.2.2 PUBLIC
12.3 CANCER CENTERS
12.4 SPECIALTY CLINICS
12.5 OTHERS
13 EUROPE UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL
13.1 OVERVIEW
13.2 DIRECT TENDER
13.3 RETAIL SALES
13.3.1 HOSPITAL PHARMACY
13.3.2 RETAIL PHARMACY
13.3.3 ONLINE PHARMACY
13.4 OTHERS
14 EUROPE UTERINE CANCER DRUGS MARKET, BY COUNTRY
14.1 EUROPE
14.1.1 GERMANY
14.1.2 U.K.
14.1.3 FRANCE
14.1.4 RUSSIA
14.1.5 ITALY
14.1.6 SPAIN
14.1.7 TURKEY
14.1.8 BELGIUM
14.1.9 NETHERLANDS
14.1.10 SWITZERLAND
14.1.11 REST OF EUROPE
15 EUROPE UTERINE CANCER DRUGS MARKET, COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: EUROPE
16 SWOT ANALYSIS
17 COMPANY PROFILES
17.1 MERCK & CO., INC.
17.1.1 COMPANY SNAPSHOT
17.1.2 REVENUE ANALYSIS
17.1.3 PRODUCT PORTFOLIO
17.1.4 RECENT DEVELOPMENT
17.2 SANOFI
17.2.1 COMPANY SNAPSHOT
17.2.2 REVENUE ANALYSIS
17.2.3 PRODUCT PORTFOLIO
17.2.4 RECENT DEVELOPMENT
17.3 EISAI CO., LTD.
17.3.1 COMPANY SNAPSHOT
17.3.2 REVENUE ANALYSIS
17.3.3 PRODUCT PORTFOLIO
17.3.4 RECENT DEVELOPMENT
17.3.5 RECENT DEVELOPMENT
17.4 PFIZER INC.
17.4.1 COMPANY SNAPSHOT
17.4.2 REVENUE ANALYSIS
17.4.3 PRODUCT PORTFOLIO
17.4.4 RECENT DEVELOPMENT
17.5 TEVA PHARMACEUTICALS USA, INC.
17.5.1 COMPANY SNAPSHOT
17.5.2 REVENUE ANALYSIS
17.5.3 PRODUCT PORTFOLIO
17.5.4 RECENT DEVELOPMENT
17.6 AMNEAL PHARMACEUTICALS LLC
17.6.1 COMPANY SNAPSHOT
17.6.2 REVENUE ANALYSIS
17.6.3 PRODUCT PORTFOLIO
17.6.4 RECENT DEVELOPMENT
17.7 BAXTER
17.7.1 COMPANY SNAPSHOT
17.7.2 REVENUE ANALYSIS
17.7.3 PRODUCT PORTFOLIO
17.7.4 RECENT DEVELOPMENT
17.8 ELI LILLY AND COMPANY
17.8.1 COMPANY SNAPSHOT
17.8.2 REVENUE ANALYSIS
17.8.3 PRODUCT PORTFOLIO
17.8.4 RECENT DEVELOPMENT
17.9 GETWELL ONCOLOGY
17.9.1 COMPANY SNAPSHOT
17.9.2 PRODUCT PORTFOLIO
17.9.3 RECENT DEVELOPMENT
17.1 GSK PLC.
17.10.1 COMPANY SNAPSHOT
17.10.2 REVENUE ANALYSIS
17.10.3 PRODUCT PORTFOLIO
17.10.4 RECENT DEVELOPMENT
17.11 HIKMA PHARMACEUTICALS PLC
17.11.1 COMPANY SNAPSHOT
17.11.2 REVENUE ANALYSIS
17.11.3 PRODUCT PORTFOLIO
17.11.4 RECENT DEVELOPMENT
17.12 SUN PHARMACEUTICAL INDUSTRIES LTD.
17.12.1 COMPANY SNAPSHOT
17.12.2 REVENUE ANALYSIS
17.12.3 PRODUCT PORTFOLIO
17.12.4 RECENT DEVELOPMENT
17.13 VIATRIS INC.
17.13.1 COMPANY SNAPSHOT
17.13.2 REVENUE ANALYSIS
17.13.3 PRODUCT PORTFOLIO
17.13.4 RECENT DEVELOPMENT
18 QUESTIONNAIRE
19 RELATED REPORTS
表格列表
TABLE 1 EUROPE UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
TABLE 2 EUROPE ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 3 EUROPE UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 4 EUROPE UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 5 EUROPE CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 6 EUROPE HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 7 EUROPE PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 8 EUROPE AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 9 EUROPE LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 10 EUROPE TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 11 EUROPE MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 12 EUROPE UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 13 EUROPE BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 14 EUROPE UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)
TABLE 15 EUROPE UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 16 EUROPE UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 17 EUROPE HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 18 EUROPE UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 19 EUROPE RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 20 EUROPE UTERINE CANCER DRUGS MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND)
TABLE 21 GERMANY UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
TABLE 22 GERMANY ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 23 GERMANY UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 24 GERMANY UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 25 GERMANY CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 26 GERMANY HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 27 GERMANY PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 28 GERMANY AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 29 GERMANY LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 30 GERMANY TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 31 GERMANY MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 32 GERMANY UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 33 GERMANY BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 34 GERMANY UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)
TABLE 35 GERMANY UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 36 GERMANY UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 37 GERMANY HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 38 GERMANY UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 39 GERMANY RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 40 U.K. UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
TABLE 41 U.K. ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 42 U.K. UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 43 U.K. UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 44 U.K. CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 45 U.K. HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 46 U.K. PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 47 U.K. AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 48 U.K. LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 49 U.K. TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 50 U.K. MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 51 U.K. UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 52 U.K. BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 53 U.K. UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)
TABLE 54 U.K. UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 55 U.K. UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 56 U.K. HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 57 U.K. UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 58 U.K. RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 59 FRANCE UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
TABLE 60 FRANCE ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 61 FRANCE UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 62 FRANCE UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 63 FRANCE CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 64 FRANCE HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 65 FRANCE PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 66 FRANCE AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 67 FRANCE LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 68 FRANCE TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 69 FRANCE MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 70 FRANCE UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 71 FRANCE BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 72 FRANCE UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)
TABLE 73 FRANCE UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 74 FRANCE UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 75 FRANCE HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 76 FRANCE UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 77 FRANCE RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 78 RUSSIA UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
TABLE 79 RUSSIA ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 80 RUSSIA UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 81 RUSSIA UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 82 RUSSIA CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 83 RUSSIA HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 84 RUSSIA PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 85 RUSSIA AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 86 RUSSIA LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 87 RUSSIA TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 88 RUSSIA MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 89 RUSSIA UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 90 RUSSIA BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 91 RUSSIA UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)
TABLE 92 RUSSIA UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 93 RUSSIA UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 94 RUSSIA HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 95 RUSSIA UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 96 RUSSIA RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 97 ITALY UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
TABLE 98 ITALY ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 99 ITALY UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 100 ITALY UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 101 ITALY CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 102 ITALY HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 103 ITALY PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 104 ITALY AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 105 ITALY LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 106 ITALY TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 107 ITALY MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 108 ITALY UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 109 ITALY BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 110 ITALY UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)
TABLE 111 ITALY UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 112 ITALY UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 113 ITALY HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 114 ITALY UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 115 ITALY RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 116 SPAIN UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
TABLE 117 SPAIN ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 118 SPAIN UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 119 SPAIN UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 120 SPAIN CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 121 SPAIN HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 122 SPAIN PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 123 SPAIN AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 124 SPAIN LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 125 SPAIN TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 126 SPAIN MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 127 SPAIN UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 128 SPAIN BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 129 SPAIN UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)
TABLE 130 SPAIN UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 131 SPAIN UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 132 SPAIN HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 133 SPAIN UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 134 SPAIN RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 135 TURKEY UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
TABLE 136 TURKEY ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 137 TURKEY UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 138 TURKEY UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 139 TURKEY CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 140 TURKEY HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 141 TURKEY PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 142 TURKEY AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 143 TURKEY LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 144 TURKEY TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 145 TURKEY MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 146 TURKEY UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 147 TURKEY BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 148 TURKEY UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)
TABLE 149 TURKEY UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 150 TURKEY UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 151 TURKEY HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 152 TURKEY UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 153 TURKEY RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 154 BELGIUM UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
TABLE 155 BELGIUM ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 156 BELGIUM UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 157 BELGIUM UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 158 BELGIUM CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 159 BELGIUM HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 160 BELGIUM PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 161 BELGIUM AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 162 BELGIUM LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 163 BELGIUM TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 164 BELGIUM MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 165 BELGIUM UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 166 BELGIUM BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 167 BELGIUM UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)
TABLE 168 BELGIUM UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 169 BELGIUM UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 170 BELGIUM HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 171 BELGIUM UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 172 BELGIUM RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 173 NETHERLANDS UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
TABLE 174 NETHERLANDS ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 175 NETHERLANDS UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 176 NETHERLANDS UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 177 NETHERLANDS CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 178 NETHERLANDS HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 179 NETHERLANDS PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 180 NETHERLANDS AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 181 NETHERLANDS LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 182 NETHERLANDS TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 183 NETHERLANDS MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 184 NETHERLANDS UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 185 NETHERLANDS BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 186 NETHERLANDS UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)
TABLE 187 NETHERLANDS UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 188 NETHERLANDS UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 189 NETHERLANDS HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 190 NETHERLANDS UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 191 NETHERLANDS RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 192 SWITZERLAND UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
TABLE 193 SWITZERLAND ENDOMETRIAL CANCER IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 194 SWITZERLAND UTERINE SARCOMA IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 195 SWITZERLAND UTERINE CANCER DRUGS MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 196 SWITZERLAND CHEMOTHERAPY IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 197 SWITZERLAND HORMONE THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 198 SWITZERLAND PROGESTINS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 199 SWITZERLAND AROMATASE INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 200 SWITZERLAND LEUTINIZING HORMONE-RELEASING HORMONE AGONISTS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 201 SWITZERLAND TARGETED THERAPY IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 202 SWITZERLAND MTOR INHIBITORS IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 203 SWITZERLAND UTERINE CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)
TABLE 204 SWITZERLAND BRANDED IN UTERINE CANCER DRUGS MARKET, BY DRUG, 2021-2030 (USD THOUSAND)
TABLE 205 SWITZERLAND UTERINE CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND)
TABLE 206 SWITZERLAND UTERINE CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 207 SWITZERLAND UTERINE CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 208 SWITZERLAND HOSPITALS IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 209 SWITZERLAND UTERINE CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 210 SWITZERLAND RETAIL SALES IN UTERINE CANCER DRUGS MARKET, BY TYPE, 2021-2030 (USD THOUSAND)
TABLE 211 REST OF EUROPE UTERINE CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD THOUSAND)
图片列表
FIGURE 1 EUROPE UTERINE CANCER DRUGS MARKET: SEGMENTATION
FIGURE 2 EUROPE UTERINE CANCER DRUGS MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE UTERINE CANCER DRUGS MARKET: DROC ANALYSIS
FIGURE 4 EUROPE UTERINE CANCER DRUGS MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS
FIGURE 5 EUROPE UTERINE CANCER DRUGS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE UTERINE CANCER DRUGS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE UTERINE CANCER DRUGS MARKET: DBMR MARKET POSITION GRID
FIGURE 8 EUROPE UTERINE CANCER DRUGS MARKET: MARKET END USER COVERAGE GRID
FIGURE 9 EUROPE UTERINE CANCER DRUGS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 EUROPE UTERINE CANCER DRUGS MARKET: SEGMENTATION
FIGURE 11 RISING INCIDENCE OF UTERINE CANCER IS DRIVING THE GROWTH OF THE EUROPE UTERINE CANCER DRUGS MARKET IN THE FORECAST PERIOD OF 2023 TO 2030
FIGURE 12 THE ENDOMETRIAL CANCER SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE UTERINE CANCER DRUGS MARKET IN THE FORECAST PERIOD OF 2023 AND 2030
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE UTERINE CANCER DRUGS MARKET
FIGURE 14 EUROPE UTERINE CANCER DRUGS MARKET: BY CANCER TYPE, 2022
FIGURE 15 EUROPE UTERINE CANCER DRUGS MARKET: BY CANCER TYPE, 2023-2030 (USD THOUSAND)
FIGURE 16 EUROPE UTERINE CANCER DRUGS MARKET: BY CANCER TYPE, CAGR (2023-2030)
FIGURE 17 EUROPE UTERINE CANCER DRUGS MARKET: BY CANCER TYPE, LIFELINE CURVE
FIGURE 18 EUROPE UTERINE CANCER DRUGS MARKET: BY TREATMENT TYPE, 2022
FIGURE 19 EUROPE UTERINE CANCER DRUGS MARKET: BY TREATMENT TYPE, 2023-2030 (USD THOUSAND)
FIGURE 20 EUROPE UTERINE CANCER DRUGS MARKET: BY TREATMENT TYPE, CAGR (2023-2030)
FIGURE 21 EUROPE UTERINE CANCER DRUGS MARKET: BY TREATMENT TYPE, LIFELINE CURVE
FIGURE 22 EUROPE UTERINE CANCER DRUGS MARKET: BY DRUG TYPE, 2022
FIGURE 23 EUROPE UTERINE CANCER DRUGS MARKET: BY DRUG TYPE, 2023-2030 (USD THOUSAND)
FIGURE 24 EUROPE UTERINE CANCER DRUGS MARKET: BY DRUG TYPE, CAGR (2023-2030)
FIGURE 25 EUROPE UTERINE CANCER DRUGS MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 26 EUROPE UTERINE CANCER DRUGS MARKET: BY AGE GROUP, 2022
FIGURE 27 EUROPE UTERINE CANCER DRUGS MARKET: BY AGE GROUP, 2023-2030 (USD THOUSAND)
FIGURE 28 EUROPE UTERINE CANCER DRUGS MARKET: BY AGE GROUP, CAGR (2023-2030)
FIGURE 29 EUROPE UTERINE CANCER DRUGS MARKET: BY AGE GROUP, LIFELINE CURVE
FIGURE 30 EUROPE UTERINE CANCER DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2022
FIGURE 31 EUROPE UTERINE CANCER DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2023-2030 (USD THOUSAND)
FIGURE 32 EUROPE UTERINE CANCER DRUGS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2023-2030)
FIGURE 33 EUROPE UTERINE CANCER DRUGS MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 34 EUROPE UTERINE CANCER DRUGS MARKET: BY END USER, 2022
FIGURE 35 EUROPE UTERINE CANCER DRUGS MARKET: BY END USER, 2023-2030 (USD THOUSAND)
FIGURE 36 EUROPE UTERINE CANCER DRUGS MARKET: BY END USER, CAGR (2023-2030)
FIGURE 37 EUROPE UTERINE CANCER DRUGS MARKET: BY END USER, LIFELINE CURVE
FIGURE 38 EUROPE UTERINE CANCER DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 39 EUROPE UTERINE CANCER DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD THOUSAND)
FIGURE 40 EUROPE UTERINE CANCER DRUGS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 41 EUROPE UTERINE CANCER DRUGS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 42 EUROPE UTERINE CANCER DRUGS MARKET: SNAPSHOT (2022)
FIGURE 43 EUROPE UTERINE CANCER DRUGS MARKET: COMPANY SHARE 2022 (%)
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
